No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
genetic polymorphisms in DNA repair genes are thought to represent important determinants of platinum drug efficacy. The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. a total of 199 platinum-treated patients with stage III-IV NSCLC were recruited. Overall survival (OS) and progression-free survival (PFS) according to genotypes and haplotypes were analyzed using Kaplan-Meier method and assessed by log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models by adjusting for clinical factors. during the median 26.5 months of follow-up, 159 deaths occurred. Regarding XRCC1 Arg194Trp, Arg280His, and Arg399Gln genotypes, no significant effects on survival were observed, although the 280Arg/His genotype was associated with a borderline-significant higher median survival time (20.0 months for Arg/His versus 16.0 months for Arg/Arg; P = 0.131). Moreover, no significant association of haplotypes with survival was found. this study showed no influence of the XRCC1 Arg194Trp, Arg280His, and Arg399Gln polymorphisms on survival in advanced NSCLC patients with platinum-based chemotherapy.